Compare CRSP & ASB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | ASB |
|---|---|---|
| Founded | 2013 | 1861 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.1B |
| IPO Year | 2016 | N/A |
| Metric | CRSP | ASB |
|---|---|---|
| Price | $57.32 | $26.13 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 12 |
| Target Price | ★ $71.50 | $27.83 |
| AVG Volume (30 Days) | ★ 2.4M | 1.6M |
| Earning Date | 11-10-2025 | 01-22-2026 |
| Dividend Yield | N/A | ★ 3.68% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.98 |
| Revenue | $38,337,000.00 | ★ $1,097,713,000.00 |
| Revenue This Year | N/A | $57.53 |
| Revenue Next Year | $723.84 | $5.33 |
| P/E Ratio | ★ N/A | $26.63 |
| Revenue Growth | N/A | ★ 8.93 |
| 52 Week Low | $30.04 | $18.32 |
| 52 Week High | $78.48 | $27.46 |
| Indicator | CRSP | ASB |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 56.79 |
| Support Level | $51.16 | $25.41 |
| Resistance Level | $59.77 | $26.14 |
| Average True Range (ATR) | 3.11 | 0.54 |
| MACD | 1.09 | 0.07 |
| Stochastic Oscillator | 80.89 | 82.21 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Associated Banc-Corp is a bank holding company. The company through its subsidiaries provides a broad array of banking and nonbanking products and services to individuals and businesses. The company operates in three reportable segments; Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty and Community, Consumer, and Business segments.